Vanguard Fiduciary Trust
DMRA

Vanguard Fiduciary Trust’s Damora Therapeutics DMRA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69M Buy
141,833
+45,169
+47% +$1.09M ﹤0.01% 2360
2026
Q1 		$2.5M Buy
+96,664
New +$2.48M ﹤0.01% 2450

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Vanguard Fiduciary Trust's DMRA Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Damora Therapeutics (DMRA) stake by 47% in Q2 2026, buying an estimated $1.09M and bringing the position to 141,833 shares worth $3.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2360.

Vanguard Fiduciary Trust first reported a position in DMRA in Q1 2026 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Vanguard Fiduciary Trust held 141,833 shares of Damora Therapeutics worth $3.69M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 45,169 Damora Therapeutics shares in Q2 2026, an estimated $1.09M.
  • Damora Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2360 holding.
  • Vanguard Fiduciary Trust first reported a position in Damora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.